Pulling SEC filings + quote and writing the call…
COGT
Cogent Biosciences, Inc.
Next earnings Aug 3, 2026 · consensus $-0.58 EPS
Last earnings +0.7% on 2026-05-05
$35.43
▲ +2.56%$34.54▲ +361.15%
over 1Y
L $7.07EODHDH $42.11
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+2.6%
1W+5.9%
1M+10.5%
3M-0.2%
YTD-0.6%
1Y+361.1%
Hold
Conviction
Horizon
Long (>12mo)
Street · 19 analysts
Buy
A late-stage, single-drug biotech (bezuclastinib) carrying a $5.6B cap on no revenue — well-funded but a binary bet on launch.
Cogent Biosciences is a clinical-stage biotech built almost entirely around bezuclastinib, a selective KIT-mutant inhibitor headed toward FDA submission and commercial launch (for systemic mastocytosis and gastrointestinal stromal tumor indications). The company has effectively no product revenue, and the financials are pure development burn: a $329M net loss (widening 28.6%), a -$333M operating loss, -$264M of operating cash flow, and R&D spend of $270M (+16.0%) as it funds pivotal programs. The negative-thousands operating margin and -51.7% ROE confirm there is no business to value on fundamentals yet — this is a probability-weighted bet on a single asset.
Sources: SEC EDGAR (CIK 0001622229, latest 10-Q filed 2026-05-05) · EODHD · analysis by claude-code · as of 6/21/2026, 8:58:49 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.